Commutable patient-matrix reference material panel for validating tumor-informed ctDNA MRD assays (RUO)
9/9
factors scored
4/4
core factors
5/51
claims verified
0
refuted
How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
claim 1unconfirmedUS
In vitro diagnostic products properly labeled "For Research Use Only. Not for use in diagnostic procedures." under 21 CFR 809.10(c) are not subject to FDA premarket notification or approval
jurisdiction: US — confidence: unconfirmed — note: labeling half now verified; the premarket half — which is the load-bearing half — is not, and the two do not stand or fall together — source: connectors regulation 809.10 --title 21 --expect "Research Use Only" --jurisdiction US → status verified, source_ref…the full checkeCFR versioner title-21, issue 2026-08-19, section=809.10. Text half — VERIFIED (re-verification pass; the regulation connector did not exist at the previous pass). 21 CFR 809.10(c)(2)(i) prescribes the exact statement verbatim: a shipment or delivery is exempt "provided that the following conditions are met: … (2) In the case of a shipment or delivery for an investigation that is not subject to part 812 (see § 812.2(c)) … (i) For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, all labeling bears the statement, prominently placed: 'For Research Use Only. Not for use in diagnostic procedures.'" Premarket half — NOT verified, and the claim mis-cites its own source. What 809.10(c) exempts is stated in its opening words: "exempt from the requirements of paragraphs (a) and (b) of this section and from a standard promulgated under part 861" — i.e. from the IVD labeling requirements and part 861 standards. It says nothing whatever about premarket notification or approval. Whether an RUO-labeled product sits outside premarket review is a question of FDA interpretation and enforcement practice (the 2013 RUO/IUO guidance — claims 2 and 3), and connectors/ecfr.py states its own scope limit explicitly: it serves regulation text, not guidance, not enforcement practice, not case law. A verified CFR citation must not be allowed to stand in for a settled interpretation, and this one does not settle it. Note further that the text imposes two conditions on the exemption it does grant — "laboratory research phase of development" and "not represented as an effective in vitro diagnostic product" — which are binding regulation text rather than guidance, and which bear directly on claim 3
claim 2unconfirmedUS
FDA guidance "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only" (issued November 2013) sets out when RUO labeling is defeated by the manufacturer's marketing conduct
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: no connector retrieves FDA guidance documents; openFDA exposes device/clearance/classification records only, and the guidance title, issue date, and content are all unchecked. **Re-attempted this pass against the newly available…the full checkregulation (eCFR) connector and it does not apply:** eCFR serves CFR text, and FDA guidance is not in the CFR — connectors/ecfr.py names this scope limit in its own docstring, calling out the 2013 RUO/IUO guidance by name as out of reach. Guidance is not binding law and lives on fda.gov as PDFs with no comparable API. Needs the PDF pulled from fda.gov and attached by a human. Structural gap — narrowed but not closed by the new connector
claim 3unconfirmedUS
Enforcement risk claim — marketing this material specifically to CLIA laboratories for validating clinical tests is exactly the conduct the 2013 RUO guidance treats as evidence that a product is not truly research use only
jurisdiction: US — confidence: unconfirmed — source: none available for the claim as stated. Verifier: this is an interpretation of a guidance document that was never retrieved (see claim 2); no connector can evaluate it, and the Verifier will not substitute its own reading of FDA policy for the text. **Remains…the full check unresolved, not dismissed** — the Generator's framing of this as the principal regulatory risk survives this pass unchecked too. What the re-verification pass did add, and it is not nothing: the condition the guidance is usually described as interpreting turns out to sit in binding regulation text, not only in guidance. Per connectors regulation 809.10 --title 21 --jurisdiction US → verified, source_ref eCFR versioner title-21, issue 2026-08-19, section=809.10, the RUO labeling exemption at 809.10(c)(2)(i) applies only "For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product." So the existence and wording of the condition is now verified primary-source text. Whether marketing this material to CLIA laboratories for validating clinical tests amounts to representing it as an effective in vitro diagnostic product is exactly the interpretive question the eCFR cannot answer — that is FDA enforcement judgment, and the connector's stated scope limit puts it out of reach. Structural gap on the interpretation; the risk is now better-specified but no closer to resolved
claim 4verifiedUS
21 CFR 862.1660 defines "quality control material (assayed and unassayed)" as a Class I device intended to estimate test precision and detect systematic analytical deviation
jurisdiction: US — confidence: verified — note: both halves — class and definitional wording — now checked; the previous pass's "class assertion only" scope caveat is lifted — source: (a) connectors classification --product-code JJX --jurisdiction US → openFDA device/classification product_code=JJX, "Device…the full check class 1: Single (Specified) Analyte Controls (Assayed And Unassayed) (regulation 862.1660, review panel CH)"; corroborated by product_code=JJY, "Device class 1: Multi-Analyte Controls, All Kinds (Assayed) (regulation 862.1660, review panel CH)" — both re-run cold this pass and unchanged. (b) connectors regulation 862.1660 --title 21 --expect "quality control material" --jurisdiction US → status verified, source_ref eCFR versioner title-21, issue 2026-08-19, section=862.1660. The regulation text itself now reads: "§ 862.1660 Quality control material (assayed and unassayed). (a) Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation… This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls. (b) Classification. Class I (general controls)." The claim's paraphrase of the definitional wording is accurate against the text, and Class I is stated in the regulation as well as in the classification database. One scope point a reader should carry: the identification clause is written "for clinical chemistry" and enumerates chemistry-type analytes; whether a contrived cfDNA panel falls inside this generic type is an FDA judgment, not something the text resolves — see claim 22
claim 5verifiedUS
Quality control materials under 862.1660 are exempt from 510(k) premarket notification except when intended for donor screening, subject to the limitations of 21 CFR 862.9
jurisdiction: US — confidence: verified — note: changed from unconfirmed this pass — both halves the previous pass called blocked are now answered from primary text — source: (a) connectors regulation 862.1660 --title 21 --jurisdiction US → status verified, source_ref `eCFR versioner title-21, issue…the full check 2026-08-19, section=862.1660. The exemption language is in the regulation verbatim and matches the claim almost word for word: "(b) Classification. Class I (general controls). **Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.**" (b) connectors regulation 862.9 --title 21 --expect "exempt" --jurisdiction US → status verified, source_ref eCFR versioner title-21, issue 2026-08-19, section=862.9`. The section exists and is titled "Limitations of exemptions from section 510(k)…". Neither gap the previous pass recorded still stands: the openFDA exemption-flag connector change is moot (the regulation, not the classification record, is where exemption language lives), and the 862.9 text no longer needs human attachment. Now read the limitations, because they cut toward this candidate. 862.9 withdraws the exemption where "(c) The device is an in vitro device that is intended: (1) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices; (2) For use in screening or diagnosis of familial or acquired genetic disorders…". A QC panel for tumor-informed MRD assays sits adjacent to (c)(1) on its face. Whether a control material for an oncology assay is itself "intended for use in the … monitoring … of neoplastic diseases" within 862.9(c)(1) is an FDA intended-use judgment, not something the text settles, and the Verifier does not resolve it here — but if it were read that way, the 510(k) exemption this claim verifies would be withdrawn and the second-SKU route would require a submission. Flagged for a human; the claim as worded is verified, its favourable implication is not
claim 6verifiedUS
One or more FDA product codes exist under regulation 862.1660 for multianalyte control materials; the Generator did not identify which code would apply and is not asserting one
jurisdiction: US — confidence: verified — source: connectors classification --product-code JJY → openFDA device/classification product_code=JJY, "Device class 1: Multi-Analyte Controls, All Kinds (Assayed) (regulation 862.1660, review panel CH)"; single-analyte companion code JJX is likewise Class 1 under 862.1660.…the full check The Generator's recorded absence of evidence is now resolved: such codes do exist. Which code would apply to a contrived cfDNA panel remains open, and see Verifier-added claim 22 — for a DNA/genetics QC material FDA has a Class II code (NZB) under a different regulation, which is material to the repositioning premise. Read claim 22 as re-verified this pass, not as originally worded: 866.5910 is scoped to cystic fibrosis nucleic acid assays and is itself 510(k)-exempt, so "Class II" there does not by itself imply a heavier premarket route
claim 7verifiedUS
42 CFR 493.1256 (CLIA) requires laboratories to perform control procedures that monitor the accuracy and precision of the complete analytic process, which is the regulatory driver of recurring demand for control material
jurisdiction: US — confidence: verified — note: regulation half — changed from unconfirmed this pass; the demand-driver half is an economic inference and is not verified, see below — source: connectors regulation 493.1256 --title 42 --expect "control procedures" --jurisdiction US → status verified,…the full check source_ref eCFR versioner title-42, issue 2026-08-13, section=493.1256. The section exists under title 42 and its text matches the claim near-verbatim: "§ 493.1256 Standard: Control procedures. (a) For each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process." The recurring-use structure is also in the text rather than inferred: "(d)(3) At least once each day patient specimens are assayed or examined perform the following for— … (v) Each molecular amplification procedure, include two control materials and, if reaction inhibition is a significant source of false negative results, a control material capable of detecting the inhibition." What the text does NOT say, and the claim's second half does. The regulation requires laboratories to run control materials; it nowhere requires that those materials be purchased from a third party rather than built in-house, and it does not require commutable or traceable material. So "regulatory driver of recurring demand for control material" is verified only in the weak sense that recurring control-material consumption is mandated. Whether that demand accrues to a commercial panel rather than to in-house contrived controls is the unverifiable purchasing-preference question at claim 21 and the moat question at claim 19, and this verified citation must not be read as answering either
claim 8unconfirmedUS
CPT code 0340U exists and describes Natera's Signatera pan-cancer tumor-informed MRD assay from plasma
jurisdiction: US — confidence: unconfirmed — source: connectors cpt 0340U → status unverifiable, source_ref null, detail: "CPT codes are AMA-licensed and cannot be scraped or reproduced verbatim (phase2-spec.md Section 3). Rescope this claim to HCPCS, or attach a licensed AMA/vendor source manually." **Permanently…the full check unconfirmed** — the open web was not searched for the descriptor and must not be. A human must attach the AMA PLA descriptor for 0340U under licence. Structural gap
claim 9unconfirmedUS
TAM component 1 — the Medicare Clinical Laboratory Fee Schedule rate for 0340U was $3,500.00 for the 7/1/21-3/31/22 period
jurisdiction: US — confidence: unconfirmed — source: connectors payment 0340U --min-expected 3500 --jurisdiction US → status unconfirmed, source_ref null, detail: "No local cache at data/hcpcs_payment_rates.csv — payment rate for 0340U cannot be checked until it exists. See data/README.md for the exact CMS source…the full check and expected columns. Do not substitute a web search for this file." Fixable-gap unconfirmed (missing CMS input file, not a permanent limit). No figure was hand-entered. Note also that the claim cites a 2021-22-period rate, not a current-year rate, and CLFS/ADLT pricing may not appear in a HCPCS fee-schedule cache at all — check the file actually carries PLA codes before treating a null as an answer
claim 10unconfirmedUS
TAM component 2 — annual Medicare claim volume for CPT 0340U exceeds 100,000 tests
jurisdiction: US — confidence: unconfirmed — source: connectors procedures 0340U --expect-volume 100000 --jurisdiction US → status unconfirmed, source_ref null, detail: "No local cache at data/medicare_procedure_volumes.csv — procedure volume for 0340U cannot be checked until it exists. See data/README.md for the…the full check exact CMS source and expected columns. Do not substitute a web search for this file." Fixable-gap unconfirmed (missing CMS input file). Standing caveat for when it is fixed: Medicare FFS utilization excludes Medicare Advantage, commercial, Medicaid, VA, and cash-pay, so a verified volume is a floor on US volume, never a market size
claim 11unconfirmedUS
TAM component 3 — reference material and external QC spend runs roughly 0.5%-1.5% of laboratory test revenue for high-complexity molecular assays
jurisdiction: US — confidence: unconfirmed — source: connectors market "..." → status unverifiable, source_ref null, detail: "Market-size claim ... has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."…the full checkPermanently unconfirmed. Structural gap
claim 12unconfirmedUS
TAM component 4 — addressable share assumption: the initial obtainable segment is the 30-60 US laboratories running or developing tumor-informed MRD assays, not the whole oncology molecular testing market
jurisdiction: US — confidence: unconfirmed — source: connectors market "..." → status unverifiable, source_ref null, same detail as claim 11. Permanently unconfirmed absent a human-attached enumeration of US labs (MolDX-registered lab list, CAP and NY CLEP directories). Structural gap
claim 13unconfirmedUS
MolDX Billing and Coding article A58456, "MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers," exists in the CMS Medicare Coverage Database
jurisdiction: US — confidence: unconfirmed — source: connectors coverage 0340U --jurisdiction US → status unconfirmed, source_ref null, detail: "No local cache at data/medicare_coverage_policies.csv — Medicare coverage policy for 0340U cannot be checked until it exists..." Two distinct gaps: (a) fixable — the…the full check CMS coverage cache is absent; (b) structural — the coverage connector keys on a HCPCS/CPT code, not on a MolDX article ID, so even a populated cache would not confirm that article A58456 specifically exists. A human must open A58456 in the CMS Medicare Coverage Database. Note also that a policy existing is not the same as positive coverage
claim 14unconfirmedUS
Reimbursement — this product has no CPT/HCPCS code and none is achievable; it is a consumable sold to laboratories, and revenue depends entirely on the customer's reimbursed test volume
jurisdiction: US — confidence: unconfirmed — source: nothing to query. Verifier: the product has no code, so there is no lookup to run; connectors hcpcs 0340U (the customer's code, not this product's) returned unconfirmed on the missing data/hcpcs_level_ii.csv cache. More importantly, even a populated file…the full check returning nothing could not establish "none is achievable" — that is a forward-looking negative about a code that does not exist, which no database can settle. The Generator's note that a null HCPCS return is "the correct result, not a gap" is accepted as a business-model statement but is not verified evidence. Structural gap
claim 15unconfirmedUS
FDA's 2024 laboratory developed test final rule was vacated by a federal district court in March 2025, so LDT-based MRD assays remain under CLIA/CAP oversight rather than FDA premarket review
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: no connector in this repo queries federal court dockets or opinions, and openFDA does not publish rulemaking status. Case name, court, docket, and date are all unchecked, and the Verifier will not resolve a legal question from its own…the full check recollection. Needs the ACLA v. FDA opinion attached by a human. Structural gap — and material to TAM in both directions
claim 16unconfirmedUS
Technical/mechanism risk — producing commutable material with a stated uncertainty budget at 0.001%-0.01% VAF is Poisson-limited at typical 10-30 ng cfDNA inputs, meaning the lowest panel levels may be irreducibly imprecise rather than merely hard to make
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: this is a bench/physics question; no connector verifies a physical claim. literature was not run as verification — it is a Stage 0 windowed PubMed scan, and returning papers on a topic neither confirms nor refutes a specific…the full check uncertainty-budget claim; treating a hit count as evidence would be exactly the summarized-search failure this gate exists to stop. Needs an internal dPCR replicate series with stated DNA input mass. Structural gap
claim 17unconfirmedUS
Competitive intensity — LGC Clinical Diagnostics (Seraseq), Revvity/Horizon Discovery, and Twist Bioscience all sell cfDNA/ctDNA reference materials today, but the Generator did not find a product specifically characterized in the sub-0.01% VAF MRD range on native-fragmentomic patient matrix
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: no connector covers RUO product catalogues. clearances and recalls were deliberately not run: RUO reference materials are never cleared, so those endpoints are silent by construction, and recording that silence would manufacture…the full check false support for the claim's negative half (the white space) — which is the half the Generator asked to be checked hard and which therefore remains entirely unchecked. Needs human-pulled vendor spec sheets and certificates of analysis recording lowest characterized VAF and matrix type per SKU. Structural gap
claim 18unconfirmedUS
FTO — no blocking patent identified over contrived cfDNA reference material composition; risk sits mainly in fragmentomic-profile and variant-spiking methods held by sequencing incumbents. No specific patent number identified
jurisdiction: US — confidence: unconfirmed — source: nothing was run; this claim is unsearched, not merely unverified. The patent connector takes a single patent_id and returns filing/grant status for that family; it cannot perform a landscape or freedom-to-operate search, and the claim names no number, so…the full check there was no query to issue. Independently, PATENTSVIEW_API_KEY is unset in this checkout, so even a numbered claim would return unconfirmed on a missing credential. Two gaps: structural (no FTO/landscape capability exists here — needs a human-commissioned search report) and fixable (set the API key to enable per-number checks). No patent-search engine was queried as a substitute
claim 19unconfirmedUS
Moat lever — the durable asset is the orthogonal characterization dataset and traceability/uncertainty documentation that a laboratory can paste into a CAP validation packet, plus lot-to-lot continuity once a lab has anchored its LoD claim to a given lot; the material itself is reproducible by any competent competitor
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: a judgment claim with no primary source and no connector. The load-bearing sub-question — whether a CAP validation packet requires, merely accepts, or ignores third-party traceable reference material — needs a human-read ISO 17034…the full check and CAP Molecular Pathology (MOL) checklist, neither of which is machine-queryable here. Structural gap
claim 20unconfirmedUS
Capital intensity — first revenue is achievable on a low-single-digit-million budget: a small wet lab, a digital PCR platform, donor plasma sourcing, and ISO 17034-oriented documentation; no instrument development, no clinical trial, no premarket submission
jurisdiction: US — confidence: unconfirmed — source: none available. Verifier: an internal cost estimate is not an external fact; no connector applies and none ever will. Note the "no premarket submission" clause inherits directly from claim 1, which is itself unconfirmed — this claim cannot be stronger than that one.…the full check Needs a human-attached bottom-up build plan (dPCR quote, donor plasma contract, ISO 17034 accreditation quote and calendar, headcount). Structural gap
claim 21unconfirmedUS
Assumption (not a checkable fact) — the idea depends on MRD laboratories preferring a third-party commutable panel over the in-house contrived controls they already build, and on their being willing to anchor a published LoD claim to an external lot. There is no connector for laboratory purchasing preference and no primary research behind this; stated here so it stays visible
jurisdiction: US — confidence: unconfirmed — source: connectors adoption "..." → status unverifiable, source_ref null, detail: "Adoption/preference claim ... asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews,…the full check survey, published preference study)... Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim." Permanently unconfirmed; no Verifier opinion was substituted. Needs named customer-discovery interviews. Structural gap
claim 22verifiedUS
Verifier-added finding (claim 22, not scored by Stage 2) — FDA classifies a genetics/DNA quality control material as Class II under regulation 866.5910, product code NZB, not as a Class I device under 862.1660
jurisdiction: US — confidence: verified — note: the Class II database fact only — the scope of the regulation and the burden inference the previous pass drew from it are both corrected below — source: (a) connectors classification --product-code NZB --jurisdiction US and `connectors classification --device-name…the full check "quality control material" --jurisdiction US → both re-run cold this pass, both returning openFDA device/classification product_code=NZB, "Device class 2: Quality Control Material, Genetics, Dna (regulation 866.5910, review panel IM)". (b) **New this pass** — connectors regulation 866.5910 --title 21 --jurisdiction US → status verified, source_ref eCFR versioner title-21, issue 2026-08-19, section=866.5910. **Contradiction with this file's own frontmatter, stated here in the claim rather than only in a scorer's note:** the frontmatter device_class comment and the indication-scope note both assert that repositioning this material as a clinical QC product lands it under 21 CFR 862.1660 as Class I. This claim asserts a **Class II** classification under a different regulation, and two independent primary sources (openFDA and the eCFR text) confirm the Class II fact. The frontmatter has **not** been edited — correcting it is a human call and is flagged as such — so the file currently carries both readings and a reader must not assume the frontmatter is the settled one. **Two corrections to what this finding actually supports, both from the regulation text the previous pass could not read:** (1) **Scope.** 866.5910 is titled "**Quality control material for cystic fibrosis nucleic acid assays**" — materially narrower than the openFDA device-name string "Quality Control Material, Genetics, Dna" makes it sound. Its identification clause covers "recombinant, synthetic, and cell line-based DNA controls" for CF nucleic acid assays. So this code is *not* a general-purpose DNA-QC classification, and it does not establish where a contrived cfDNA MRD panel would land. (2) **Burden — and this cuts against the previous pass's inference.** 866.5910(b) reads: "Class II (special controls). **The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.** The special control is FDA's guidance document entitled 'Class II Special Controls Guidance Document: Quality Control Material for Cystic Fibrosis Nucleic Acid Assays.'" **Class II here does not mean a 510(k) is required** — this section is 510(k)-exempt on its face, as 862.1660 is. The previous pass's conclusion that a Class II code "directly undercuts the repositioning premise" and that "the second-SKU route cannot be treated as low-burden" therefore **overstates what the record supports**: the difference between the two candidate regulations is a special-controls guidance obligation, not the presence or absence of a premarket submission. **866.9 sub-point — RESOLVED this pass, and it cuts back against the correction above.** The previous pass recorded connectors regulation 866.9 --title 21 as unconfirmed on eCFR HTTP 503 and correctly logged the limitations as unchecked rather than absent. The outage was transient: connectors regulation 866.9 --title 21 --expect "For use in the diagnosis, monitoring, or screening of neoplastic diseases" --jurisdiction US → status verified, source_ref eCFR versioner title-21, issue 2026-08-19, section=866.9 (several attempts still returned unconfirmed on 503/read-timeout before one succeeded — eCFR is flaky, not silent, and a single 503 must not be read as an answer). **The section exists, is titled "Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act)", and is the direct structural parallel of 862.9 — including, verbatim, the same limitation that matters at claim 5.** Three parts of the text bear on the 866.5910 route: (i) the preamble limits any part-866 exemption to devices with "existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality"; (ii) a premarket notification is still required where "(a) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device" or "(b) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device"; and (iii) **"(c) The device is an in vitro device that is intended: (1) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices; (2) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism…"** — 866.9(c)(1) is word-for-word 862.9(c)(1). **What this changes and what it does not.** The claim's tag is **unchanged at verified`: the Class II / NZB / 866.5910 database fact and the fact that 866.5910(b) is 510(k)-exempt on its face both still stand on primary sources, and nothing here refutes them. What changes is the detail, in the same shape as claim 5: the 866.5910 exemption is now verified to **exist and is not verified to apply. The previous pass's correction — that the difference between the two candidate regulations is a special-controls guidance obligation rather than a submission — holds only if the exemption survives 866.9, and 866.9 is now read and is not obviously survivable. Two limbs point at this candidate on their face: (c)(1), since the material's whole purpose is validating tumor-informed MRD assays, and (a), since 866.5910's generic type is scoped to cystic fibrosis nucleic acid assays, so a contrived cfDNA MRD panel is on its face intended for a different use than the legally marketed devices in that generic type. Neither is resolved here. Whether a control material for an oncology assay is itself "intended for use in the … monitoring … of neoplastic diseases", and whether an MRD panel is a "different intended use" within the CF generic type, are FDA intended-use judgments the text does not settle and the Verifier does not make; flagged for a human alongside the identical question at claim 5. Bearing on claim 5, stated here rather than by editing that claim: the 862.9(c)(1) neoplastic-disease limitation recorded there is not escapable by choosing the 866.5910 route — the two sections carry the identical limitation, so the same open FDA judgment gates the 510(k) exemption on both candidate regulations for the clinical-QC second SKU. Claim 5's own text and tag are untouched by this pass. What remains true and open: which regulation a contrived cfDNA MRD panel would actually fall under — 862.1660, 866.5910, or neither — is an FDA intended-use determination for a human, and per claim 5 the 862.9(c)(1) neoplastic-disease limitation is the sharper live question on the 862.1660 route
claim 23unconfirmedUS
Laboratories running or developing tumor-informed MRD assays currently build in-house contrived controls and find them inadequate at sub-0.01% variant allele fraction
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — detail: connectors adoption "<claim>" → status unverifiable. Adoption/stakeholder-preference claim: no free, authoritative source answers this; needs primary research (interviews, survey, published…the full check preference study). Permanently unconfirmed absent human-attached research.
claim 24unconfirmedUS
A CAP inspector or CLIA assessor accepts a third-party commutable reference panel with a published uncertainty budget as validation evidence supporting a laboratory's limit-of-detection claim
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — detail: Regulatory interpretation claim about CAP/CLIA practice. Needs human-read CAP Molecular Pathology (MOL) checklist and CLIA regulations to determine whether third-party traceable material is required,…the full check merely accepted, or irrelevant to validation packets. No connector applies.
claim 25unconfirmedUS
Laboratories will accept lot-to-lot continuity risk from a single external supplier for a limit-of-detection claim they publish
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — detail: connectors adoption "<claim>" → status unverifiable. Adoption/stakeholder-preference claim: whether laboratories accept supplier continuity risk. No connector applies; needs primary…the full check customer-discovery interviews with MRD laboratory directors.
claim 26unconfirmedUS
Assay-development scientists select reference material directly and can purchase it as a consumable, without a capital-procurement process
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — detail: connectors adoption "<claim>" → status unverifiable. Adoption/stakeholder-preference claim: whether scientists can purchase consumables directly without capital approval. No connector applies;…the full check needs primary customer-discovery interviews with assay-development teams.
claim 27unconfirmedUS
Reference-material purchasing at MRD laboratories is recurring, at a cadence tied to assay runs and periodic revalidation, rather than a one-time development purchase
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — detail: connectors adoption "<claim>" → status unverifiable. Adoption/stakeholder-preference claim: whether laboratories make recurring vs. one-time purchases. No connector applies; needs primary…the full check customer-discovery interviews about purchasing cadence and patterns.
claim 28unconfirmedUS
The 30-60 laboratory segment can be reached by a direct technical sales motion without a distributor
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — detail: connectors adoption "<claim>" → status unverifiable. Adoption/business-model claim: whether direct sales motion is feasible for this segment. No connector applies; needs primary sales-motion…the full check research and customer conversations with laboratory procurement contacts.
claim 29unconfirmedUS
Panel price multiplied by that laboratory count supports a standalone business rather than a product line inside a larger reagent company
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — detail: Business-model viability claim. Rests on unconfirmed TAM components (claims 9-12: pricing, volume, market spend %, addressable segment). Cannot be verified without those component claims resolving.…the full check Needs bottom-up financial modeling by a human.
claim 30unconfirmedUS
Pooled human donor plasma can be sourced at a scale and consistency that preserves the native cell-free DNA fragmentomic profile lot over lot
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — detail: Technical/procurement claim about donor plasma sourcing and lot-to-lot consistency. No connector applies; needs human-attached vendor contracts and sourcing specifications establishing reproducibility…the full check of fragmentomic profile across lots.
claim 31unconfirmedUS
Commutability against clinical patient samples can be demonstrated across the major tumor-informed MRD assay chemistries, rather than asserted from the matrix choice
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — detail: Technical claim about assay commutability. No connector applies; needs human-attached commutability study data demonstrating cross-platform compatibility against real clinical MRD specimens.
claim 32unconfirmedUS
Panel levels at the lowest allele fractions are stable through freeze-thaw, shipping and the stated shelf life within the published uncertainty budget
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — detail: Technical/stability claim. No connector applies; needs human-attached stability and shipping data documenting material integrity through freeze-thaw cycles, transport, and storage within claimed shelf…the full check life and uncertainty bounds.
claim 33unconfirmedUS
ISO 17034 reference-material-producer accreditation is achievable on the stated budget and timeline
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — detail: Regulatory/timeline claim. No connector applies. Claim 20 depends on this; both need human-attached ISO 17034 accreditation quotes from an accrediting body (e.g. A2LA) with stated timeline and…the full check calendar, plus bottom-up cost estimate.
claim 34unconfirmedUS
Haystack MRD's analytical validation demonstrated a 95% limit of detection of 0.063 mean ctDNA molecules/mL and an analytical measurement range of 0.25-1,000 mean ctDNA molecules/mL
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 42624249 → PubMed PMID=42624249 (efetch), Journal of Molecular Diagnostics 2026. Abstract states: "Haystack MRD demonstrated a 95% limit of detection of 0.063 mean ctDNA molecules/mL and an analytical measurement range of 0.25-1,000…the full check mean ctDNA molecules/mL." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 35unconfirmedUS
The CancerDetect (AlphaLiquid Detect) hybrid tumor-informed/tumor-agnostic MRD assay's analytical validation reached a limit of detection of 0.001% (10^-5) variant allele fraction at 99.9% specificity
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 41212866 → PubMed PMID=41212866 (efetch), PLoS ONE 2025. Abstract states: "The analytical validation result of CancerDetectTM showed limit of detection successfully reached down to 0.001% (10-5) with 99.9% specificity." — evidence…the full check class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 36unconfirmedUS
The NeXT Personal ctDNA assay's analytical validation reported a 95% limit of detection (LOD95) of 3.45 parts per million (approximately 0.000345% VAF), linear from 0.8 to 300,000 ppm
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 38484152 → PubMed PMID=38484152 (efetch), Oncotarget 2024. Abstract states: "Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM... NeXT…the full check Personal showed linearity over a range of 0.8 to 300,000 PPM (Pearson correlation coefficient = 0.9998)." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 37unconfirmedUS
The Invitae Personalized Cancer Monitoring assay's limit of detection ranged from 0.008% VAF at 60 ng cfDNA input to 0.05% VAF at 10 ng cfDNA input, both at greater than 99.9% sensitivity
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 37632661 → PubMed PMID=37632661 (efetch), Molecular Diagnosis & Therapy 2023. Abstract states: "Limit of detection ranged from 0.008% allele frequency when utilizing 60 ng of cfDNA input with 18-50 variants in the patient-specific…the full check panels (> 99.9% sensitivity)... to 0.05% allele frequency when using 10 ng of cfDNA input with an 18-variant panel with a monitoring threshold (> 99.9% sensitivity)." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 38unconfirmedUS
A tumor-informed ctDNA monitoring method (GeneBits/umiVar) benchmarked on three commercial cfDNA reference standards (Twist Pan-Cancer v2, Horizon Multiplex I, Horizon OncoSpan) achieved a limit of detection as low as 0.0017% variant allele fraction with no false-positive calls in mutation-free reference samples
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 40866952 → PubMed PMID=40866952 (efetch), Journal of Translational Medicine 2025. Abstract states: "umiVar enabled variant detection at a limit of detection as low as 0.0017%, with no false positive calls in mutation-free reference…the full check samples." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 39unconfirmedUS
In a multi-manufacturer study of a multiplex cfDNA reference material, coefficient of variation increased with decreasing mutant allele fraction and poor repetition occurred when the allele fraction was lower than 0.5%, across eight manufacturers' NGS platforms
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 30405853 → PubMed PMID=30405853 (efetch), Journal of Cancer 2018. Abstract states: "The coefficient of variation (CV) was increased with decreasing mutant allelic frequency, and poor repetition occurred when the allelic frequency was…the full check lower than 0.5%." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 40unconfirmedUS
An 89-laboratory external quality assurance program for cfDNA variant testing used reference material with predicted allele fractions of 0.5%-2.5% and found greater than 92% of laboratories concordant by z-score proficiency testing
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 31487000 → PubMed PMID=31487000 (efetch), Pathology Oncology Research 2020. Abstract states: "A total of 89 laboratories participated in this EQA program... The predicted genotypic variant allelic frequencies ranged between 0.5% -…the full check 2.5%... Z-score proficiency testing found that >92% of clinical laboratories were concordant for detecting the cfDNA variants." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 41unconfirmedUS
In the DYNAMIC-III randomized trial (n=968 evaluable stage III colon cancer patients), ctDNA-negative patients had a significantly higher 3-year recurrence-free survival than ctDNA-positive patients (87% versus 49%, P<0.001)
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 41115959 → PubMed PMID=41115959 (efetch), Nature Medicine 2025. Abstract states: "Among 968 evaluable patients... ctDNA-negative patients experienced significantly fewer recurrences than ctDNA-positive patients (3-year RFS 87% versus…the full check 49%; P < 0.001)." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 42unconfirmedUS
In the ALTAIR randomized phase 3 trial (n=243), post-adjuvant treatment triggered by ctDNA-detected molecular residual disease did not significantly improve disease-free survival versus placebo (hazard ratio 0.79, 95% CI 0.60-1.05, P=0.107), and the primary endpoint was not met
jurisdiction: US — confidence: unconfirmed — source: connectors literature-detail 42260101 → PubMed PMID=42260101 (efetch), Nature Medicine 2026. Abstract states: "Between July 2020 and June 2023, 243 patients were randomized to FTD/TPI (n = 122) or placebo (n = 121)... Median DFS was 9.30 months with FTD/TPI and…the full check 5.55 months with placebo (hazard ratio = 0.79, 95% confidence interval: 0.60-1.05, P = 0.107), and the primary endpoint was not met." — evidence class 2 (published finding) Verifier correction (2026-08-29):literature-detail returns a ScanResult with no confidence field by construction (docs/research-lane-spec.md §3, connectors/result.py) — a single-source abstract match cannot resolve to verified; content confirmed accurate as quoted, tag held at unconfirmed on structural grounds, consistent with every other Verifier pass in this repo (idea-001, idea-002, idea-005, idea-007, idea-008, idea-009).
claim 43unconfirmedUS
Natera reported that clinical molecular residual disease (Signatera) oncology test unit volume grew by 34,000 units in Q2 2026 versus Q1 2026, the largest sequential increase in the company's history to that date
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier ctdna-mrd-assay-validation §4 (2026-08-27) — detail: Natera press release (2026-08-06) is a vendor/press-release-only source with no connector available. No endpoint in this repo verifies company earnings or press-release claims;…the full check generic web search is not permitted as a substitute. Verifier could not retrieve or confirm the specific unit-volume figure. — evidence class 2 (published finding)
claim 44unconfirmedUS
Guardant Health reported that Guardant Reveal test volume grew more than 100% year-over-year in Q2 2026, its third consecutive quarter of greater than 100% year-over-year growth
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier ctdna-mrd-assay-validation §4 (2026-08-27) — detail: Guardant Health earnings call transcript (2026-07-30, published by The Motley Fool) is a press/earnings-only source with no connector available. No endpoint in this repo verifies…the full check company earnings transcripts; generic web search is not permitted as a substitute. Verifier could not retrieve or confirm the specific growth figures. — evidence class 2 (published finding)
claim 45unconfirmedUS
LGC/SeraCare's Seraseq ctDNA Reference Material v4 product line's lowest characterized variant allele fraction is 0.1%, supplied in a vendor-described 'plasma like matrix' rather than pooled human donor plasma
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier ctdna-mrd-assay-validation §4 (2026-08-27) — detail: Vendor product specification (LGC/SeraCare website) with no PMID and no connector available. No endpoint in this repo verifies vendor product catalogues; generic web search is not…the full check permitted as a substitute. Verifier could not retrieve or confirm the specific product specifications (VAF range, matrix type, etc.). — evidence class 2 (published finding)
claim 46unconfirmedUS
Horizon Discovery (Revvity) cfDNA reference standards are manufactured from fragmented human cell-line genomic DNA (average 160 bp) spiked into a synthetic plasma matrix, with allele fractions offered down to 0.1%
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier ctdna-mrd-assay-validation §4 (2026-08-27) — detail: Vendor product specification (Horizon Discovery FAQ page) with no PMID and no connector available. No endpoint in this repo verifies vendor product catalogues; generic web search is…the full check not permitted as a substitute. Verifier could not retrieve or confirm the specific product specifications (matrix composition, fragment size, VAF range, etc.). — evidence class 2 (published finding)
claim 47unverifiedUS
By year 3, a third-party commercial reference panel captures at least a low double-digit percentage share of addressable US MRD-laboratory reference-material spend, rather than losing that spend to in-house contrived controls or the three incumbent commercial vendors
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 48unverifiedUS
A molecular laboratory or assay manufacturer will pay a per-panel price materially above the incumbent commercial reference-material vendors' list price (LGC Seraseq, Horizon/Revvity HDx, Twist Bioscience) for a panel characterized into the sub-0.01% VAF range
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 49unverifiedUS
The gross margin earned on the panel, once donor-plasma sourcing, orthogonal dPCR characterization, and ISO 17034-oriented documentation costs are included, is high enough to support a standalone reference-material business at the addressable laboratory count and purchase cadence
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 50unverifiedUS
First commercial shipment of a characterized panel to a paying laboratory customer is achievable within the same low-single-digit-million capital budget and a calendar of roughly 9-15 months from a standing start
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it
claim 51unverifiedUS
An existing reference-material vendor (LGC Clinical Diagnostics, Revvity/Horizon Discovery, or Twist Bioscience) would license or acquire sub-0.01%-VAF characterization and orthogonal dPCR quantification methodology rather than build it in-house, at a cost and calendar lower than fielding an independent direct-sales channel to the 30-60 laboratory segment
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-03) — never checked; recorded so the Verifier can see it